BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34376108)

  • 1. The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease.
    Yang X; Ma F; Bai M; Wang Y; Jia Q; Dong R; Liu C; Sun S
    Ren Fail; 2021 Aug; 43(1):1180-1187. PubMed ID: 34376108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy.
    Tan L; Tang Y; Peng W; Mathew BS; Qin W
    Kidney Blood Press Res; 2018; 43(4):1333-1343. PubMed ID: 30099439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.
    Ma F; Yang X; Zhou M; Bai M; Zhao L; Li L; Dong R; Liu C; Li R; Sun S
    J Nephrol; 2020 Dec; 33(6):1241-1250. PubMed ID: 32447619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy.
    Sarcina C; Tinelli C; Ferrario F; Pani A; De Silvestri A; Scaini P; Del Vecchio L; Alberghini E; Buzzi L; Baragetti I; Pozzi C
    Clin J Am Soc Nephrol; 2016 Jun; 11(6):973-981. PubMed ID: 27129712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.
    Tesar V; Troyanov S; Bellur S; Verhave JC; Cook HT; Feehally J; Roberts IS; Cattran D; Coppo R;
    J Am Soc Nephrol; 2015 Sep; 26(9):2248-58. PubMed ID: 25677392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria.
    Pei G; Tan J; Tang Y; Tan L; Zhong Z; Zhou L; Chen C; Qin W
    Medicine (Baltimore); 2020 Jun; 99(24):e20513. PubMed ID: 32541473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive agents for treating IgA nephropathy.
    Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
    Zhong Z; Tang Y; Tan J; Tan L; Pei G; Qin W
    Int Urol Nephrol; 2021 Jan; 53(1):121-127. PubMed ID: 32944888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.
    Rauen T; Fitzner C; Eitner F; Sommerer C; Zeier M; Otte B; Panzer U; Peters H; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JFE; Hilgers RD; Floege J
    J Am Soc Nephrol; 2018 Jan; 29(1):317-325. PubMed ID: 29042456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents.
    Chen J; Xu H; Peng Z; Lin L; Li C; Zhu X; Liu S
    Clin Exp Nephrol; 2020 Jan; 24(1):73-81. PubMed ID: 31605314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
    Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
    Zhang X; Shi S; Ouyang Y; Yang M; Shi M; Pan X; Lv J; Wang Z; Ren H; Shen P; Wang W; Zhang H; Xie J; Chen N
    J Transl Med; 2018 May; 16(1):115. PubMed ID: 29724226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of IgA nephropathy patients with less than 25% crescents and mild proteinuria.
    Jia Q; Ma F; Yang X; Li L; Liu C; Sun R; Li R; Sun S
    Clin Exp Nephrol; 2022 Mar; 26(3):257-265. PubMed ID: 34724588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.
    Hou FF; Xie D; Wang J; Xu X; Yang X; Ai J; Nie S; Liang M; Wang G; Jia N;
    JAMA Netw Open; 2023 Feb; 6(2):e2254054. PubMed ID: 36745456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study.
    Rivedal M; Haaskjold YL; Eikrem Ø; Bjørneklett R; Marti HP; Knoop T
    BMC Nephrol; 2024 Jan; 25(1):42. PubMed ID: 38287343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-year GFR slope and long-term renal outcome in IgA nephropathy.
    Lee K; Shin J; Park J; Hwang S; Jang HR; Huh W; Kwon GY; Kim YG; Oh HY; Lee JE; Kim DJ
    Eur J Clin Invest; 2018 Jun; 48(6):e12936. PubMed ID: 29660832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of cytotoxic therapy in progressive IgA nephropathy.
    Shin JH; Lee JE; Park JH; Lim S; Jang HR; Kwon GY; Huh W; Jung SH; Kim YG; Oh HY; Kim DJ
    Ann Med; 2016; 48(3):171-81. PubMed ID: 27031662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience.
    Wu H; Fang X; Xia Z; Gao C; Peng Y; Li X; Zhang P; Kuang Q; Wang R; Wang M
    J Nephrol; 2020 Dec; 33(6):1263-1273. PubMed ID: 32507961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.